Is the demand seriously that companies provide everything potentially relevant coming from their clinical trials? Or, to be cynical, is the requested change to process limited to trial outcomes supporting efforts to secure price reductions? …
Latest Video
New Stories
-
A scrapped website, almost $100 million, and the politics of what really matters
November 23, 2025 - - Latest News -
Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD
November 22, 2025 - - Australian Biotech -
Syntara launches Phase 2 trial aiming to teduce transfusion burden in myelodysplastic syndromes
November 22, 2025 - -
Alterity Therapeutics chairman reflects on two decades of progress as company enters new era
November 22, 2025 - - BioPharma -
Treasurer blocks US takeover of Mayne Pharma on national interest grounds
November 22, 2025 - - Latest News -
If the system properly applied results in harm, then the problem is worse than we think
November 20, 2025 - - Latest News -
Silence in response to unethical processes and outcomes is itself unethical
November 20, 2025 - - Latest News